Soleno Therapeutics Inc.
Soleno Therapeutics Appoints Experienced CFO Mark W. Hahn to Board
Summary
On October 13, 2025, Soleno Therapeutics, Inc. announced the appointment of Mark W. Hahn, a seasoned biopharmaceutical executive with nearly 30 years of CFO experience, to its Board of Directors and the Audit Committee. Mr. Hahn's extensive background in leading successful product launches, financings, and M&A transactions within the life sciences sector is expected to benefit Soleno as it continues to execute its commercial launch of VYKAT XR, a treatment for hyperphagia in Prader-Willi syndrome patients. In connection with his appointment, Mr. Hahn received a grant of 10,046 restricted stock units and executed an indemnification agreement. The press release detailing this appointment is furnished as Exhibit 99.1 to the 8-K filing.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement